Endocrinology

In this edition of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Jennifer Clements, PharmD, following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management.

The participants who initiated insulin after implementation achieved significantly higher doses at 36 weeks.

Glargine and detemir insulin were modestly associated with a reduced risk of MACE compared to neutral protamine Hagedorn insulin.

Participants in the least deprived group had one quarter the odds of no change/increase in mean HbA1c compared with the most deprived group.

26 weeks of treatment with empagliflozin reduced the myocardial glucose metabolic rate by 45.1% in patients with type 2 diabetes.

Gary Scheiner, MS, CDE, discusses updates in diabetes technologies from the ADCES annual meeting, the role of CDES in optimizing uptake and use of new technology, and the ADCES's push to advance diabetes management.

In this episode, the hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with ADCES 2022 Diabetes Care and Education Specialist of the Year Anastasia Albanese-O’Neill, PhD, to discuss her inspiration, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

In this special edition ADCES 22 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by David Walton, CEO of the T1D Exchange, who takes our hosts on a deep dive into the history of the organization, what it is doing right now to improve patient care, and how it expects to grow and improve management of type 1 diabetes into the future.

In this special edition of Diabetes Dialogue recorded on-site at ADCES 22, our hosts are joined by Korey Hood, PhD, a staff psychologist and professor at Stanford University. Founder of DiabetesWise and DiabetesWisePro, Hood talks to Diana Isaacs, PharmD, and Natalie Bellini, DNP, about his efforts and how the online resources are pushing care forward.

Scott Kahan, MD, MPH, discusses the concept of weight stigma, its historical impact, and avenues for confronting weight stigma that currently exists in clinical care settings.

Data from a 14-week randomized clinical trial suggests adherence to a time-restricted diet was associated with significant differences in weight loss and improvements in blood pressure compared to a typical diet.

On August 5, Pfizer announced the FDA's approval of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg (MYFEMBREE) for the management of moderate to severe pain associated with endometriosis in premenopausal women for up to 24 months.

Dr. Gregory Weiss provides perspective on a recent study examining associations between serum ceramide levels and the likelihood of achieving normoglycemia among patients who have undergone RYGB.

A national coalition of more than 20 health professional organizations and patient representatives, the WPSI recommendation for preventing obesity in midlife women advocates for counseling to maintain weight or limit weight gain among women with normal or overweight BMI aged 40-60 years.

A retrospective study provides insight into the ability of CGM technology to improve glycemic control in in-hospital settings and, potentially, reduce the risk of spreading infectious diseases.

Dr. Gregory Weiss provides perspective on a recent study in Pediatrics describing the increased incidence of childhood obesity in the US and what it might mean for clinicians moving forward.

An analysis of a prospective cohort study in China provides evidence suggesting poor sleep behaviors, including daytime napping and nighttime sleep disturbances, could increase risk of metabolic dysfunction-associated fatty liver disease.

Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.

The highest adjusted probability of CGM use occurred in middle adulthood, while the probability of CGM utilization decreased with increasing age in older adulthood.

For the July 2022 episode of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.

A trial assessing a 12-week fully automated, no-cost online education program suggests participation in the program was linked to a mean weight loss of 5.1% of starting body weight, with greater levels of participation linked to greater weight loss among participants.

New data report a slightly higher but nonsignificant increase in diabetes incidence among children in Canada during COVID-19 pandemic.

The new recommendation acknowledges the role of disease-preventive behaviors that can be taken on by approximately 12% of the US population.

Jennifer Green, MD, discusses the benefit of relatively new innovations including continuous glucose monitoring and smart insulin pens.